Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.
Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence on immunogenicity of biologics used in the treatment of psoriasis and considers the implications for therapeutic decision-making in the management of patients with moderate-to-severe psoriasis.
Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
J-M
JM
Carrascosa
M B A
MB
van Doorn
M
M
Lahfa
F O
FO
Nestle
D
D
Jullien
J C
JC
Prinz
D001688:Biological Products / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019468:Disease Management; D006801:Humans; D056724:Immunity, Humoral / Q000235:genetics / Q000276:immunology / Q000502:physiology; D055261:Immunogenetic Phenomena / Q000502:physiology*; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha